Cargando…

Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy

Background: CAMP response element binding protein 3-like 1 (CREB3L1) has been indicated as a critical biomarker and can modulate multifaced behaviors of tumor cells in diverse cancers. However, a systematic assessment of CREB3L1 in pan-cancer is of absence, and the predictive value of CREB3L1 in can...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Zhengjun, Wu, Yanlin, Xiao, XunGang, Zhang, Xianghong, Wan, Jia, Zheng, Tao, Chen, Hongxuan, Liu, Tang, Tang, Xianzhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511413/
https://www.ncbi.nlm.nih.gov/pubmed/36171879
http://dx.doi.org/10.3389/fgene.2022.938510
_version_ 1784797636550721536
author Lin, Zhengjun
Wu, Yanlin
Xiao, XunGang
Zhang, Xianghong
Wan, Jia
Zheng, Tao
Chen, Hongxuan
Liu, Tang
Tang, Xianzhe
author_facet Lin, Zhengjun
Wu, Yanlin
Xiao, XunGang
Zhang, Xianghong
Wan, Jia
Zheng, Tao
Chen, Hongxuan
Liu, Tang
Tang, Xianzhe
author_sort Lin, Zhengjun
collection PubMed
description Background: CAMP response element binding protein 3-like 1 (CREB3L1) has been indicated as a critical biomarker and can modulate multifaced behaviors of tumor cells in diverse cancers. However, a systematic assessment of CREB3L1 in pan-cancer is of absence, and the predictive value of CREB3L1 in cancer prognosis, the tumor immune microenvironment and the efficacy of immunotherapy remains unexplored. Methods: CREB3L1 expression in 33 different cancer types was investigated using RNAseq data from The Cancer Genome Atlas (TCGA) database. The characteristics of CREB3L1 alternations were illustrated in cBioPortal database. The prognostic and clinicopathological value of CREB3L1 was analyzed through clinical data downloaded from the TCGA database. The potential role of CREB3L1 in the tumor immune microenvironment was illustrated by utilizing CIBERSORT and ESTIMATE algorithms, and TISIDB online database. The associations between CREB3L1 expression and tumor mutation burden (TMB), and microsatellite instability (MSI) were assessed by spearman’s rank correlation coefficient. Furthermore, Gene Set Enrichment Analysis (GSEA) was conducted to explore the potential biological functions and downstream pathways of CREB3L1 in different human cancers. The correlations of CREB3L1 expression with PD-1/PD-L1 inhibitors efficacy and drug sensitivity were also investigated. Results: The expression of CREB3L1 was abnormally high or low in several different cancer types, and was also strictly associated with the prognosis of cancer patients. CREB3L1 expression levels have a strong relationship with infiltrating immune cells, including regulatory T cells, CD8(+) T cells, macrophages, B naïve cells, dendritic cells and mast cells. CREB3L1 expression was also correlated with the expression of multiple immune-related biomolecules, TMB, and MSI in several cancers. Moreover, CREB3L1 had promising applications in predicting the immunotherapeutic benefits and drug sensitivity in cancer management. Conclusions: Our results highlight the value of CREB3L1 as a predictive biomarker for the prognosis and immunotherapy efficacy in multiple cancers, and CREB3L1 seems to play key roles in the tumor immune microenvironment, suggesting the role of CREB3L1 as a promising biomarker for predicting the prognosis and immune-related signatures in diverse cancers.
format Online
Article
Text
id pubmed-9511413
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95114132022-09-27 Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy Lin, Zhengjun Wu, Yanlin Xiao, XunGang Zhang, Xianghong Wan, Jia Zheng, Tao Chen, Hongxuan Liu, Tang Tang, Xianzhe Front Genet Genetics Background: CAMP response element binding protein 3-like 1 (CREB3L1) has been indicated as a critical biomarker and can modulate multifaced behaviors of tumor cells in diverse cancers. However, a systematic assessment of CREB3L1 in pan-cancer is of absence, and the predictive value of CREB3L1 in cancer prognosis, the tumor immune microenvironment and the efficacy of immunotherapy remains unexplored. Methods: CREB3L1 expression in 33 different cancer types was investigated using RNAseq data from The Cancer Genome Atlas (TCGA) database. The characteristics of CREB3L1 alternations were illustrated in cBioPortal database. The prognostic and clinicopathological value of CREB3L1 was analyzed through clinical data downloaded from the TCGA database. The potential role of CREB3L1 in the tumor immune microenvironment was illustrated by utilizing CIBERSORT and ESTIMATE algorithms, and TISIDB online database. The associations between CREB3L1 expression and tumor mutation burden (TMB), and microsatellite instability (MSI) were assessed by spearman’s rank correlation coefficient. Furthermore, Gene Set Enrichment Analysis (GSEA) was conducted to explore the potential biological functions and downstream pathways of CREB3L1 in different human cancers. The correlations of CREB3L1 expression with PD-1/PD-L1 inhibitors efficacy and drug sensitivity were also investigated. Results: The expression of CREB3L1 was abnormally high or low in several different cancer types, and was also strictly associated with the prognosis of cancer patients. CREB3L1 expression levels have a strong relationship with infiltrating immune cells, including regulatory T cells, CD8(+) T cells, macrophages, B naïve cells, dendritic cells and mast cells. CREB3L1 expression was also correlated with the expression of multiple immune-related biomolecules, TMB, and MSI in several cancers. Moreover, CREB3L1 had promising applications in predicting the immunotherapeutic benefits and drug sensitivity in cancer management. Conclusions: Our results highlight the value of CREB3L1 as a predictive biomarker for the prognosis and immunotherapy efficacy in multiple cancers, and CREB3L1 seems to play key roles in the tumor immune microenvironment, suggesting the role of CREB3L1 as a promising biomarker for predicting the prognosis and immune-related signatures in diverse cancers. Frontiers Media S.A. 2022-09-09 /pmc/articles/PMC9511413/ /pubmed/36171879 http://dx.doi.org/10.3389/fgene.2022.938510 Text en Copyright © 2022 Lin, Wu, Xiao, Zhang, Wan, Zheng, Chen, Liu and Tang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Lin, Zhengjun
Wu, Yanlin
Xiao, XunGang
Zhang, Xianghong
Wan, Jia
Zheng, Tao
Chen, Hongxuan
Liu, Tang
Tang, Xianzhe
Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy
title Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy
title_full Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy
title_fullStr Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy
title_full_unstemmed Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy
title_short Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy
title_sort pan-cancer analysis of creb3l1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511413/
https://www.ncbi.nlm.nih.gov/pubmed/36171879
http://dx.doi.org/10.3389/fgene.2022.938510
work_keys_str_mv AT linzhengjun pancanceranalysisofcreb3l1asbiomarkerinthepredictionofprognosisandimmunotherapeuticefficacy
AT wuyanlin pancanceranalysisofcreb3l1asbiomarkerinthepredictionofprognosisandimmunotherapeuticefficacy
AT xiaoxungang pancanceranalysisofcreb3l1asbiomarkerinthepredictionofprognosisandimmunotherapeuticefficacy
AT zhangxianghong pancanceranalysisofcreb3l1asbiomarkerinthepredictionofprognosisandimmunotherapeuticefficacy
AT wanjia pancanceranalysisofcreb3l1asbiomarkerinthepredictionofprognosisandimmunotherapeuticefficacy
AT zhengtao pancanceranalysisofcreb3l1asbiomarkerinthepredictionofprognosisandimmunotherapeuticefficacy
AT chenhongxuan pancanceranalysisofcreb3l1asbiomarkerinthepredictionofprognosisandimmunotherapeuticefficacy
AT liutang pancanceranalysisofcreb3l1asbiomarkerinthepredictionofprognosisandimmunotherapeuticefficacy
AT tangxianzhe pancanceranalysisofcreb3l1asbiomarkerinthepredictionofprognosisandimmunotherapeuticefficacy